^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Melanoma
    Drug:BNT111 (Immunostimulant, NY ESO 1 inhibitor, MAGE-A3 inhibitor, Protein tyrosine phosphatase inhibitor, Tyrosinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    BioNTech Press Release
    Title:

    BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma

    Published date:
    11/19/2021
    Excerpt:
    BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for BNT111, an investigational cancer immunotherapy for the potential treatment of advanced melanoma.